Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Equity Ratio: 2009-2025

Historic Equity Ratio for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to 0.86.

  • Gyre Therapeutics' Equity Ratio rose 9.65% to 0.86 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.86, marking a year-over-year increase of 9.65%. This contributed to the annual value of 0.78 for FY2024, which is 677.74% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Equity Ratio of 0.86 as of Q3 2025, which was up 1.67% from 0.85 recorded in Q2 2025.
  • Gyre Therapeutics' Equity Ratio's 5-year high stood at 0.95 during Q2 2022, with a 5-year trough of -2.28 in Q2 2023.
  • Moreover, its 3-year median value for Equity Ratio was 0.77 (2024), whereas its average is 0.19.
  • As far as peak fluctuations go, Gyre Therapeutics' Equity Ratio tumbled by 340.91% in 2023, and later spiked by 677.74% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Equity Ratio (Quarterly) stood at 0.74 in 2021, then rose by 15.43% to 0.85 in 2022, then tumbled by 115.94% to -0.14 in 2023, then skyrocketed by 677.74% to 0.78 in 2024, then grew by 9.65% to 0.86 in 2025.
  • Its last three reported values are 0.86 in Q3 2025, 0.85 for Q2 2025, and 0.80 during Q1 2025.